Elemary Toka, Nicola Mina, Abdelrahim Mohamed E A, Zaafar Dalia
Clinical Pharmacy Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Mol Biol Rep. 2025 Apr 17;52(1):400. doi: 10.1007/s11033-025-10458-7.
Patients diagnosed with type 2 diabetes have an increased risk of developing cardiovascular complications. The researchers are currently working on understanding how to prevent these progressions from occurring. Since 2006, dipeptidyl-peptidase-4 inhibitors have been made available to patients as a relatively new treatment for diabetes. These substances inhibit the enzyme known as dipeptidyl peptidase-4 (DPP-4), which in turn increases the levels of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This results in an increase in the effectiveness of insulin release after meals, which in turn has a positive impact on glycemic control. Regarding the safety of this category of medication in the treatment of cardiovascular disorders, there have been a great deal of debates. Emerging research suggests that DPP-4 inhibitors could be useful in the treatment of a variety of cardiovascular conditions, including coronary atherosclerosis, heart failure, and hypertension, among others. In order to investigate the possibility of using dipeptidyl-peptidase-4 inhibitors as a treatment option for cardiovascular disease, the molecular pathways that are thought to be responsible for their cardioprotective effect will be clarifies throughout the course of this review.
被诊断为2型糖尿病的患者发生心血管并发症的风险增加。研究人员目前正在致力于了解如何预防这些病情进展的发生。自2006年以来，二肽基肽酶-4抑制剂已作为一种相对较新的糖尿病治疗药物提供给患者。这些物质抑制名为二肽基肽酶-4（DPP-4）的酶，这反过来又会增加葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）的水平。这导致餐后胰岛素释放的有效性增加，进而对血糖控制产生积极影响。关于这类药物在治疗心血管疾病方面的安全性，已经有很多争论。新出现的研究表明，DPP-4抑制剂可能对治疗多种心血管疾病有用，包括冠状动脉粥样硬化、心力衰竭和高血压等。为了研究使用二肽基肽酶-4抑制剂作为心血管疾病治疗选择的可能性，在本综述过程中将阐明被认为是其心脏保护作用原因的分子途径。
